Tacrolimus for Crohn's disease

Ruddock B
Issues in Emerging Health Technologies 2006, (88): 1-4
(1) Tacrolimus (FK-506) is an immunosuppressant that is being investigated for use in patients with Crohn's disease, mainly in those with refractory illness and fistulizing patterns of the disease. (2) Evidence from a small, randomized controlled trial indicates that, compared with placebo, tacrolimus is associated with higher rates of improvement and similar rates of remission in those with fistulizing patterns of disease. (3) Nephrotoxicity, which has been reported with the use of tacrolimus in clinical trials, seems to improve with dose reduction, but may be associated with irreversible histologic changes. (4) More studies are needed to determine the optimal dose and duration of therapy, and whether the drug is beneficial to patients with non-fistulizing patterns of Crohn's disease.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"